BioMedNewsBreaks Archive - Page 59 of 242

TuesdayJul 09, 2024 11:10 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has announced that four new executives will be joining the company’s management team. The four new leaders include Mark White as chief business officer; Alexander Morris, PhD, as director of strategic communications; Hilda Maibach as senior vice president of statistics; and Blake Jensen as head of quality. White is currently serving as a board member and has held positions of increasing responsibility at Pfizer, Bracco, Abbott and Bayer. Most recently, he was vice president of worldwide…

TuesdayJul 09, 2024 10:45 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Effect 1-for-20 Reverse Stock Split

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. ET on July 11, 2024. According to the announcement, Clene’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the company’s existing symbol CLNN at the beginning of trading on July 11. The reverse stock split, for which Equiniti Trust Company LLC…

MondayJul 08, 2024 11:47 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced its receipt of an updated non-binding letter of intent (“LoI”) from the European Investment Bank (“EIB”). The updated LoI outlines specific terms for converting the majority of the EIB’s loan into equity in the form of preferred shares, which are convertible into American Depositary Shares (“ADSs”) representing 19.5% of the fully diluted capital of the company at the time of closing. According to the announcement, the number of ADSs into which…

FridayJul 05, 2024 2:55 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements, which are for the purchase and sale of 1,425,000 shares of common stock, are comprised of a registered direct offering and warrants. The offering and warrants are to purchase up to 1,425,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.39 per share. The offering is expected to close today, subject to customary closing…

FridayJul 05, 2024 11:29 am

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed an amended and restated material change report. According to the announcement, the report amended the disclosure in Section 5.1 of the original MCR. “The amended and restated material change report is being filed to provide additional disclosure with respect of the private placement offering of Class A multiple voting shares of the company that closed on Dec. 5, 2023,” stated the company in the press release. “The amended and restated MCR can be found on…

TuesdayJul 02, 2024 10:53 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting on its financial results for the quarter ended March 31, 2024; the company also released a business update. Notable financial numbers include R&D expenses for the three-month period totaling $1,568,000; marketing, general and administrative expenses totaling $484,000; financial income totaling $231,000; and net loss reported at $2,159,000; the company also reported cash and cash equivalents and short-term deposits of $4,826,000 as of March 31, 2024. Business highlights include raising $1.69 million in gross proceeds…

TuesdayJul 02, 2024 10:25 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands E-Commerce Program in China

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that it has expanded its e-commerce development program in China through a new agreement with a leading Chinese healthcare and nutritional products marketing and distribution services partner (the “marketing partner”). According to the update, the marketing partner will provide NextPlat with a full range of creative content, brand marketing and product sales and distribution services and support the company’s exclusive joint e-commerce development agreement with OPKO Health Europe , a subsidiary of OPKO Health, Inc. (NASDAQ: OPK). “Our unique e-commerce development program was created to provide American companies with turn-key…

TuesdayJul 02, 2024 10:08 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD study. According to the report, study findings indicate that buntanetap, the company’s proprietary drug candidate, is safe and effective in improving motor and nonmotor activities and improving cognitive functions in patients with early Parkinson’s disease. Specifically, buntanetap stopped cognitive decline in all enrolled patients and improved cognition in patients with mild dementia, improved motor and nonmotor PD-related functions in patients with a diagnosis of more than three years,…

MondayJul 01, 2024 2:00 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorders, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for using suramin to treat Human African Trypanosomiasis (“HAT”), a well-established treatment in East Africa for nearly a century. A recent article discussed PaxMedica gearing up for a significant Type C meeting it had with the FDA, which “is critical for the advancement of PAX-101, the company’s leading drug candidate for treating autism, as it progresses through the regulatory framework… For PaxMedica, this Type C meeting is a strategic opportunity to engage with…

MondayJul 01, 2024 12:13 pm

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that it has partnered with Totaligent Inc. (OTC: TGNT) to assist the company in its efforts to enhance its market awareness. According to the announcement, FSD Pharma retained the services of Totaligent with an objective to “foster productive, continuing dialogues with shareholders and other market participants.” Totaligent brings more than two decades of experience in market-awareness campaigns to the table; the company also has a database of 32 million active investors, which it communicates with through email,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Effect 1-for-20 Reverse Stock Split

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands E-Commerce Program in China

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search